Table 4.
Response rates with chemotherapy for recurrent or metastatic disease.
| 1st line chemotherapy | All lines of chemotherapy (1, 2, 3) | |
|---|---|---|
| Doxorubicin-based regimens | ||
| CR | 2 (20%) | 3 (18.7%) (AI (2), ADIC) |
| PR | 2 (20%) | 2 (12.5%) (AI, VAI) |
| (CR + PR) | 4 (40%) | 5 (31.2%) |
| SD | 5 (50%) | 9 (56.3%) (AI (4), ADIC, Dox (3), CyA) |
| (CR + PR + SD) | 9 (90%) | 14 (87.5%) |
| PD | 1 (10%) | 2 (12.5%) (AI, Dox) |
| Total patients | 10 | 16 |
| Gemcitabine/docetaxel | ||
| CR | 1 (12.5%) | 1 (7.1%) |
| PR | 1 (12.5%) | 1 (7.1%) |
| (CR + PR) | 2 (25%) | 2 (14.3%) |
| SD | 3 (37.5%) | 6 (42.9%) |
| (CR + PR + SD) | 5 (62.5%) | 8 (57.1%) |
| PD | 3 (37.5%) | 6 (42.9%) |
| Total patients | 8 | 14 |
| Platinum-based regimens | ||
| CR | 0 | 0 |
| PR | 0 | 1 (20%) (Cis/Ifos) |
| (CR + PR) | 0 | 1 (20%) |
| SD | 3 (100%) | 4 (80%) (Cis/Gem, Cis + XRT, carbo/taxol (2)) |
| (CR + PR + SD) | 3 (100%) | 5 (100%) |
| PD | 0 | 0 |
| Total patients | 3 | 5 |
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AI, doxorubicin/ifosfamide; ADIC, doxorubicin/dacarbazine; VAI, vincristine/doxorubicin/ifosfamide; Dox, doxorubicin; CyA, doxorubicin/cyclophosphamide; Cis, cisplatin; Ifos, ifosfamide; Gem, gemcitabine; carbo, carboplatin; XRT, radiation; taxol, paclitaxel.